Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor

Table 1

Patient characteristics before ASCT.

Pt#	Sex	Age at diagnosis (years)	Initial disease sites	Initial/induction therapy	Response to induction	Second line therapy	Diagnosis to ASCT (months)
First complete remission before ASCT
1	F	11.9	Abdomen, pelvis	P6	CR	None	7.6
2	M	14.8	Abdomen, pelvis	P6	CR	None	7.6
3	M	15.0	Abdomen, pelvis	P6	CR	None	5.8
4	M	16.1	Abdomen, mediastinum	P6	CR	None	9.5
5	M	22.4	Abdomen, pelvis	P6	CR	None	5.7
6	M	24.1	Abdomen, pelvis	P6	CR	None	10.2
7	M	24.3	Abdomen, pelvis	P6	CR	None	6.8
8	F	47.7	Abdomen, mediastinum	P6	CR	None	10.1
Persistent but chemosensitive disease before ASCT
9	M	10.0	Abdomen, pelvis	NB therapy followed by P6	PR	None	16.1
10	M	13.0	Abdomen, pelvis	P6	PR	None	7.8
11	F	13.6	Abdomen, pelvis, mediastinum, neck	P6	PR	None	9.8
12	M	16.3	Abdomen, pelvis	P6	PR	None	6.1
13	M	17.1	Abdomen, pelvis	P6	PR	None	9.1
14	M	20.7	Abdomen, pelvis, mediastinum	CAV/CTV	PR	None	7.9
15	M	31.7	Abdomen, pelvis, mediastinum	P6	PR	None	6.8
16	M	32.5	Abdomen, pelvis, neck	P6	PR	High-dose cyclophosphamide	10.7
Relapse before ASCT
17	M	18.5	Testes	Surgery; observation	Not applicable	P6	25.3
18	M	22.4	Abdomen, mediastinum	P6	CR	High-dose cyclophosphamide; surgery	22.4
19	M	26.9	Abdomen, pelvis, neck	P6	PD	High-dose cyclophosphamide + topotecan	12.5

ASCT: autologous stem cell transplant; CAV: high-dose cyclophosphamide plus doxorubicin and vincristine; CR: complete remission; CTV: high-dose cyclophosphamide plus topotecan and vincristine; F: female; M: male; NB: neuroblastoma; P6: P6 protocol; PD: progressive disease; PR: partial remission.